Citations

Clear

4847 citation(s) found for "Yu, Eric".

Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder
Sosero, Yuri L., Yu, Eric, Estiar, Mehrdad A., Krohn, Lynne, Mufti, Kheireddin, Rudakou, Uladzislau, Ruskey, Jennifer A., Asayesh, Farnaz, Laurent, Sandra B., Spiegelman, Dan, Trempe, Jean-François, Quinnell, Timothy G., Oscroft, Nicholas, Arnulf, Isabelle, Montplaisir, Jacques Y., Gagnon, Jean-François, Desautels, Alex, Dauvilliers, Yves, Gigli, Gian Luigi, Valente, Mariarosaria, Janes, Francesco, Bernardini, Andrea, Sonka, Karel, Kemlink, David, Oertel, Wolfgang, Janzen, Annette, Plazzi, Giuseppe, Antelmi, Elena, Biscarini, Francesco, Figorilli, Michela, Puligheddu, Monica, Mollenhauer, Brit, Trenkwalder, Claudia, Sixel-Döring, Friederike, Cock, Valérie Cochen De, Monaca, Christelle Charley, Heidbreder, Anna, Ferini-Strambi, Luigi, Dijkstra, Femke, Viaene, Mineke, Abril, Beatriz, Boeve, Bradley F., Postuma, Ronald B., Rouleau, Guy A., Ibrahim, Abubaker, Stefani, Ambra, Högl, Birgit, Hu, Michele T.M., Gan-Or, Ziv, Arnulf, Isabelle , Stefani, Ambra , Heidbreder, Anna , Puligheddu, Monica , Figorilli, Michela , Janes, Francesco , Bernardini, Andrea , Ibrahim, Abubaker , Biscarini, Francesco , Stefani, Ambra , Bernardini, Andrea , Arnulf, Isabelle , Ibrahim, Abubaker , Janes, Francesco , Figorilli, Michela , Puligheddu, Monica , Biscarini, Francesco , Heidbreder, Anna , Sosero, Yuri L., Yu, Eric, Estiar, Mehrdad A., Krohn, Lynne, Mufti, Kheireddin, Rudakou, Uladzislau, Ruskey, Jennifer A., Asayesh, Farnaz, Laurent, Sandra B., Spiegelman, Dan, Trempe, Jean-François, Quinnell, Timothy G., Oscroft, Nicholas, Montplaisir, Jacques Y., Gagnon, Jean-François, Desautels, Alex, Dauvilliers, Yves, Gigli, Gian Luigi, Valente, Mariarosaria, Sonka, Karel, Kemlink, David, Oertel, Wolfgang, Janzen, Annette, Plazzi, Giuseppe, Antelmi, Elena, Mollenhauer, Brit, Trenkwalder, Claudia, Sixel-Döring, Friederike, Cock, Valérie Cochen De, Monaca, Christelle Charley, Ferini-Strambi, Luigi, Dijkstra, Femke, Viaene, Mineke, Abril, Beatriz, Boeve, Bradley F., Postuma, Ronald B., Rouleau, Guy A., Ibrahim, Abubaker, Högl, Birgit, Hu, Michele T.M., Gan-Or, Ziv

Mayo Clinic

Journal of Parkinson's Disease | October 20, 2021 | Volume: 12 | Issue: 1 | Pages: 333-340

10.3233/jpd-212867 | PMID 34690151 Get It

Background: PSAP encodes saposin C, the co-activator of glucocerebrosidase, encoded by GBA. GBA mutations are associated with idiopathic/isolated REM sleep behavior disorder (iRBD), a prodromal stage of synucleinopathy. Objective: To examine the role of PSAP mutations in iRBD. Methods: We fully sequenced PSAP and performed Optimized Sequence Kernel Association Test in 1,113 iRBD patients and 2,324 controls. We identified loss-of-function (LoF) mutations, which are very rare in PSAP, in three iRBD patients and none in controls (uncorrected p = 0.018). Results: Two variants were stop mutations, p.Gln260Ter and p.Glu166Ter, and one was an in-frame deletion, p.332_333del. All three mutations have a deleterious effect on saposin C, based on in silico analysis. In addition, the two carriers of p.Glu166Ter and p.332_333del mutations also carried a GBA variant, p.Arg349Ter and p.Glu326Lys, respectively. The co-occurrence of these extremely rare PSAP LoF mutations in two (0.2%) GBA variant carriers in the iRBD cohort, is unlikely to occur by chance (estimated co-occurrence in the general population based on gnomAD data is 0.00035%). Although none of the three iRBD patients with PSAP LoF mutations have phenoconverted to an overt synucleinopathy at their last follow-up, all manifested initial signs suggestive of motor dysfunction, two were diagnosed with mild cognitive impairment and all showed prodromal clinical markers other than RBD. Their probability of prodromal PD, according to the Movement Disorder Society research criteria, was 98% or more. Conclusion: These results suggest a possible role of PSAP variants in iRBD and potential genetic interaction with GBA, which requires additional studies.
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Kwan, Tanya T. , Tinker, Anna V. , Oaknin, Ana , Aghajanian, Carol , Lorusso, Domenica , Colombo, Nicoletta , Dean, Andrew , Weberpals, Johanne I. , Severson, Eric A. , Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara , Harding, Thomas , McNeish, Iain A. , Lin, Kevin K. , Swisher, Elizabeth M. , McNeish, Iain A , Swisher, Elizabeth M , Oza, Amit M. , Ray-Coquard, Isabelle L. , Kaufmann, Scott H. , Ledermann, Jonathan A. , Coleman, Robert L.

Mayo Clinic

JAMA Oncology | October 18, 2021 | Volume: 7 | Issue: 12 | Pages: 1772

10.1001/jamaoncol.2021.4664 | PMID 34647981 Get It

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Rollot, Fabien , Mondot, Lydiane, Louapre, Céline , Page, Emmanuelle Le , Durand‐Dubief, Françoise , Labauge, Pierre, Bensa, Caroline , Thouvenot, Éric , Ciron, Jonathan , Bourre, Bertrand , Cabre, Philippe, Casez, Olivier , Ruet, Aurélie , Mathey, Guillaume , Berger, Éric , Moreau, Thibault, Khedr, A. Al, Derache, Nathalie, Guennoc, Anne‐Marie, Créange, Alain , Neau, Jean‐Philippe, Tourbah, Ayman , Camdessanché, Jean‐Philippe , Maarouf, Adil , Callier, Céline, Kantarci, Orhun H. , Sıva, Aksel , Azevedo, Christina , Makhani, Naila , Pelletier, Daniel , Investigators, RISC, SFSEP, and OFSEP, Pelletier, Daniel, Azevedo, Christina, Radji, Fataï, Morel, Nathalie, Grosset-Jeannin, Deborah, Ungureanu, Aurelian , Boyer, L, Suchet, Laurent , Elias, Zyad, Brochet, Bruno, Defer, Gilles , Branger, Pierre , Clavelou, Pierre, Taithe, Frédéric, Alkhedr, Adullatif, Fromont, Agnès, Hautecoeur, Patrick, Androdias, G. , Ionescu, Iuliana, Pelletier, Jean , Audoin, Bertrand , Labauge, Pierre, Debouverie, Marc, Laplaud, David, Wiertlevski, Sandrine, Bresch, Saskia , Castelnovo, Giovanni, Papeix, Caroline , Lubetzki, Catherine , Stankoff, Bruno, Fontaine, Bertrand , Giannesini, C. , Heinzleff, Olivier, Bourre, Bertrand, Gout, Olivier , Guegen, Antoine, Leray, Emmanuelle , Guennoc, Anne Marie , Broucker, T. de , Sehaki, Sabrina, Devys-Meyer, Nathalie, Bereau, Mathieu, Cappe, Chrystelle, Kounkou, Katy-Kim, Dumont, Émilie , Lescieux, Edwige, Protin, Alexia, Kane, Maty Diop, Boucher, Julie, Petit, Julie, Kasonde, Irène Tabellah, Vilmarrest, Aymeric de, Nicol, Marie , Malbezin, Muriel, Olaiz, Javier, Rigaud-Bully, Claire, Vukusic, Irena, Debard, Nadine, Cotton, François, Abdelalli, Amalle, Lelio, Bernadette Di, Pinna, Frédéric , Guillemin, Francis, Ziegler, Amandine, Zehrouni, Karima, Hodel, Jérôme , Wahab, Abir , Zedet, Mickaël, Fagniez, Ombeline, Laage, Clémence, Pottier, Corinne , Slesari, Iuliana, Sampaio, Mathilde, Rabois, Emilie, Castex, Cédric , Hébant, Benjamin , Guillaume, Maxime , Vimont, Christine, Muraz, Romain, Port, Damien Le, Henry, Carole , Berthe, Carole, Freitas, Noellie, Visneux, Vincent, Forestier, M., Beltran, S. , Meunier, Géraldine, Servan, Jérôme, Pico, Fernando, Chatagner, Virginie, Siva, Aksel , Thouvenot, Eric , Ciron, Jonathan , Durand-Dubief, Françoise , Lebrun‐Frénay, Christine , Mondot, Lydiane , Zéphir, Hélène , Laplaud, David , Seze, Jerome De , Bourre, Bertrand , Casez, Olivier , Clavelou, Pierre , Vermersch, Patrick , Cohen, Mikaël , Okuda, Darin T. , Vukusic, Sandra , Investigators, RISC, SFSEP, and OFSEP, Azevedo, Christina, Morel, Nathalie, Boyer, Latine, Ouallet, Jean‐Christophe , Clavelou, Pierre, Outteryck, Olivier , Hautecoeur, Patrick, Ayrignac, Xavier , Carra‐Dallière, Clarisse , Labauge, Pierre, Laplaud, David, Maillart, Elisabeth , Bourre, Bertrand, Michel, Laure , Magy, Laurent , Collongues, Nicolas , Biotti, Damien , Béreau, Matthieu , Casey, Romain , Muraz, Romain, Forestier, Melanie

Mayo Clinic

JAMA Network Open | October 17, 2021 | Volume: 4 | Issue: 10 | Pages: e2128271

10.1001/jamanetworkopen.2021.28271 | PMID 34633424 Get It

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
Alwan, Laura, Bachiashvili, Kimo, Cool, Rita, Curtin, Peter , Gojo, Ivana , Kidwai, Wajih Zaheer, Kloth, Dwight D. , Kraut, Eric H., Perez, Lia, Rosovsky, Rachel , Vasu, Sumithira , Wadleigh, Martha , Westervelt, Peter, Griffiths, Elizabeth A. , Brown, Anna Mary , Geyer, Mark Blaine , Kallam, Avyakta , Lyman, Gary H , Mukherjee, Sudipto , Roy, Vivek , Rugo, Hope S. , Becker, Pamela S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 13, 2021 | Volume: 19 | Issue: 13 | Pages: 18-21

10.6004/jnccn.2020.7610 | PMID 32871558 Get It

Hematopoietic growth factors, including erythrocyte stimulating agents (ESAs), granulocyte colony-stimulating factors, and thrombopoietin mimetics, can mitigate anemia, neutropenia, and thrombocytopenia resulting from chemotherapy for the treatment of cancer. In the context of pandemic SARS-CoV-2 infection, patients with cancer have been identified as a group at high risk of morbidity and mortality from this infection. Our subcommittee of the NCCN Hematopoietic Growth Factors Panel convened a voluntary group to review the potential value of expanded use of such growth factors in the current high-risk environment. Although recommendations are available on the NCCN website in the COVID-19 Resources Section (https://www.nccn.org/covid-19/), these suggestions are provided without substantial context or reference. Herein we review the rationale and data underlying the suggested alterations to the use of hematopoietic growth factors for patients with cancer in the COVID-19 era.
Diversity Matters: A 21-Year Review of Trends in Resident Recruitment into Surgical Specialties
Mohan, Anita T. , Banuelos, Joseph, Cespedes-Gomez, Omar, Kapoor, Trishul , Moran, Steven L. , Heller, Stephanie F. , Dozois, Eric J. , Nelson, Heidi, Stulak, John M., Martinez‐Jorge, Jorys

Mayo Clinic

Annals of Surgery Open | October 13, 2021 | Volume: 2 | Issue: 4 | Pages: e100

10.1097/as9.0000000000000100 | PMID 37637873 Get It

Background: Diversity within the healthcare workforce is essential to improve quality of care, although evaluation of diversity within surgical training remains limited. This study analyzed diversity in recruitment of residents into surgical subspecialties at a large academic medical institution and national trends. Methods: A 21-year cross-sectional study of medical school graduates accepted into all surgical subspecialty training programs was performed. The institutional cohort was divided into two groups (1997–2006, 2007–2017). Subspecialty acceptance rates were determined between 2011 and 2018. Data on candidate demographics including gender, race, ethnicity, citizenship, and origin of medical education at a single institution and nationally were extracted. Results: Two thousand found hundred seventy-two residents were included in this study. From 1997 to 2018, female acceptances increased from 21.1% to 29.7% (p < 0.01), non-White increased from 27.9% to 31.8% (p = 0.01), and international medical graduates decreased from 28.8% to 25.5% (p = 0.02). There was no significant change in accepted Hispanic and Non-US candidates. Female subspecialty rates for subspecialties increased nationally and was comparable to our cohort, except in general surgery. Hispanic subspecialty acceptance rates were less than 10% and Black/African American acceptance rates remained less than 5% across subspecialties nationally and at our institution. Conclusion: Diversity in surgical training has modestly progressed over the last two decades, but the degree of positive change has not been universal and highlights the critical need for improvement and action. Continued institution driven and collaborative strategies are essential to promote diversity in recruitment across all surgical specialties that has implications on our future workforce and surgical leadership.
Elbow Torque May be Predictive of Anatomic Adaptations to the Elbow After a Season of Collegiate Pitching: A Dynamic Ultrasound Study
Khalil, Lafi S. , Jildeh, Toufic R. , Klochko, Chad , Scher, Courtney, Muh, Stephanie , Moutzouros, Vasilios , Okoroha, Kelechi R. , Abbas, Muhammad J. , Holsbeeck, Marnix van , Makhni, Eric Chugh

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | October 12, 2021 | Volume: 3 | Issue: 6 | Pages: No page available

10.1016/j.asmr.2021.08.012 | PMID 34977639 Get It

Purpose To determine whether elbow torque was associated with anatomic adaptations of the medial elbow following a season of competitive pitching. Methods Pitchers from 3 collegiate baseball teams were recruited during the preseason for participation. Before the season, pitchers were recorded throwing 5 “game‐speed” fastball pitches from a standard distance off a mound while wearing a wearable sensor baseball compression sleeve that calculates elbow torque, arm speed, arm slot, and arm rotation. Participants subsequently underwent dynamic ultrasound imaging of the medial elbow, including measurements of the ulnar collateral ligament (UCL) and ulnohumeral joint space to assess elbow laxity. Following a full season of competitive pitching, all testing was repeated, and statistical analysis comparing preseason to postseason sonographic findings was performed. Results Twenty‐eight collegiate pitchers underwent preseason sonographic and kinematic testing. Nineteen pitchers were available for postseason testing. The average age (standard deviation) and playing experience was 19.9 (1.2) and 14.7 (1.5) years. Compared with preseason, there were significant increases in postseason UCL thickness (1.92 ± 0.09 vs 1.56 ± 0.09 mm, P < .01) and elbow laxity (1.77 ± 0.23 vs 1.15 ± 0.22 mm, P = .028) after a season of pitching. No significant changes in pitching kinematic measurements were observed between preseason and postseason testing. Preseason pitching kinematic measurements were significantly associated with increased UCL thickness (arm slot: beta estimate –0.03 ± 0.01, P = .011) and reduction in elbow laxity (elbow torque: beta estimate –0.03 ± 0.01, P = .04) after a season of pitching. Pitchers with increased body weight and arm length demonstrated reduced medial elbow torque during pitching ( P < .05). Conclusions After a season of competitive pitching, adaptive changes of the medial elbow were demonstrated on dynamic ultrasound. However, the influence of pitching kinematic measurements on these adaptations are of small magnitude and unknown clinical significance. Although wearable sensor technology may have value in trending individual pitcher kinematics, no discrete threshold appears to predict the development of adaptive changes at the elbow. Level of Evidence Level II, prospective observational study.
Generalized methodology for radiomic feature selection and modeling in predicting clinical outcomes
Yang, Jing , Xu, Lei , Wan, Yidong , Yen, Eric, Chen, Feng , Lu, Zhongjie, Rong, Yi , Niu, Tianye , Rong, Yi , Niu, Tianye , Yang, Pengfei , Luo, Chen , Lu, Yun He

Mayo Clinic

Physics in Medicine & Biology | October 11, 2021 | Volume: 66 | Issue: 21 | Pages: 215005

10.1088/1361-6560/ac2ea5 | PMID 34633308 Get It

Abstract Background. Quantitative radiomic features of medical images could provide clinical significance in assisting decision-making, but the existing feature selection and modeling methods are usually parameter-dependent. We aim to develop and validate a generalized radiomic method applicable to a variety of clinical outcomes. Methods and materials. A generalized methodology for radiomic feature selection and modeling (‘GRFM’ for short), including two-step feature selection and logistic regression, was proposed for studying clinical outcomes correlations. The two-step feature selection consists of Pearson correlation analysis followed by a sequential forward floating selection algorithm to identify robust feature subsets. We also applied an adaptive searching strategy to systematically determine globally optimal parameters, rather than relying on preset parameters. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of three outcomes: lymph node metastasis of gastric cancer (GC), the five-year survival status of high-grade osteosarcoma (HOS), and the pathological grade of pancreatic neuroendocrine tumors (pNETs). Results. The optimal Pearson thresholds were 0.85, 0.80 and 0.75, and the optimal feature numbers were 11, 14 and 8 in GC, HOS and pNETs, respectively. The AUC values of the three predictive models combined with the corresponding parameters were 0.9017 versus 0.9026, 0.7652 versus 0.7113, and 0.8438 versus 0.8212 for the training and validation cohorts, showing promissing generality and classifier performance . Conclusion. The proposed method was helpful in predicting different clinical outcomes, and has potential application as a general and noninvasive prediction tool to guide clinical decision-making in various cancer sites.
A High-Sensitivity International Knee Documentation Committee Survey Index From the PROMIS System: The Next-Generation Patient-Reported Outcome for a Knee Injury Population
Robins, Richard J. , Sheean, Andrew J. , Dekker, Travis J. , Collaborative, MOTION, Bailey, James R. , Bharmal, Husain, Bradley, Matthew W. , Cameron, Kenneth L. , Burns, Travis C. , Freedman, Brett A. , Grenier, Eric, Haley, Chad A., Hurvitz, Andrew P. , Mauntel, Timothy C. , McDonald, Lucas S. , Nesti, Leon J. , Posner, Matthew, Provencher, Matthew T. , Roach, Christopher J., Slabaugh, Mark A. , Tucker, Christopher J. , Volk, William R., Dickens, Jonathan F. , Dickens, Jonathan F , Tenan, Matthew S. , Collaborative, MOTION, Galvin, Joseph W. , LeClere, Lance E. , Lee, Ian , Owens, Brett D. , Potter, Benjamin Kyle , Rhon, Daniel I. , Ryan, Paul M. , Schmitz, Matthew R.

Mayo Clinic

The American Journal of Sports Medicine | October 6, 2021 | Volume: 49 | Issue: 13 | Pages: 3561-3568

10.1177/03635465211041593 | PMID 34612705 Get It

Background: Patient-reported outcomes (PROs) measure progression and quality of care. While legacy PROs such as the International Knee Documentation Committee (IKDC) survey are well-validated, a lengthy PRO creates a time burden on patients, decreasing adherence. In recent years, PROs such as the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function and Pain Interference surveys were developed as computer adaptive tests, reducing time to completion. Previous studies have examined correlation between legacy PROs and PROMIS; however, no studies have developed effective prediction models utilizing PROMIS to create an IKDC index. While the IKDC is the standard knee PRO, computer adaptive PROs offer numerous practical advantages. Purpose: To develop a nonlinear predictive model utilizing PROMIS Physical Function and Pain Interference to estimate IKDC survey scores and examine algorithm sensitivity and validity. Study Design: Cohort study (diagnosis); Level of evidence, 3. Methods: The MOTION (Military Orthopaedics Tracking Injuries and Outcomes Network) database is a prospectively collected repository of PROs and intraoperative variables. Patients undergoing knee surgery completed the IKDC and PROMIS surveys at varying time points. Nonlinear multivariable predictive models using Gaussian and beta distributions were created to establish an IKDC index score, which was then validated using leave-one-out techniques and minimal clinically important difference analysis. Results: A total of 1011 patients completed the IKDC and PROMIS Physical Function and Pain Interference, providing 1618 complete observations. The algorithms for the Gaussian and beta distribution were validated to predict the IKDC (Pearson = 0.84-0.86; R 2 = 0.71-0.74; root mean square error = 9.3-10.0). Conclusion: The publicly available predictive models can approximate the IKDC score. The results can be used to compare PROMIS Physical Function and Pain Interference against historical IKDC scores by creating an IKDC index score. Serial use of the IKDC index allows for a lower minimal clinically important difference than the conventional IKDC. PROMIS can be substituted to reduce patient burden, increase completion rates, and produce orthopaedic-specific survey analogs.
Prevention of acute exacerbation of chronic obstructive pulmonary disease after bronchoscopic lung volume reduction with endobronchial valves
Lee‐Mateus, Alejandra Yu , Garcia‐Saucedo, Juan C. , Saifi, Omran , Patel, Neal M. , Herth, Felix , Woytanowski, J.R. , Alshelli, Ihab, Alevas, Sajive, Becerra, Juan Pablo Uribe, Majid, Adnan , Edell, Eric S. , Dulohery-Scrodin, Megan, Reisenauer, Janani , Jantz, Michael A., Abbas, Hawazin K., Fernández-Bussy, Sebastián , Yu Lee-Mateus, Alejandra, Dulohery-Scrodin, Megan M, Reisenauer, Janani S, Yu Lee-Mateus, Alejandra , Abia‐Trujillo, David , Mehta, Hiren J.

Mayo Clinic

The Clinical Respiratory Journal | October 5, 2021 | Volume: 16 | Issue: 1 | Pages: 43-48

10.1111/crj.13450 | PMID 34605606 Get It

AbstractIntroductionBronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs) has emerged as an important treatment method for patients with severe chronic obstructive pulmonary disease (COPD). Acute exacerbations of COPD (AECOPD) are a frequent complication following BLVR with EBV. However, there is no consensus on the prevention of AECOPD.ObjectivesOur study aims to compare the outcomes of different prophylactic measures on the occurrence of AECOPD after BLVR with EBV.MethodsWe conducted a multicenter, retrospective study of patients who underwent BLVR with EBV at six different institutions. Emphasis was directed towards the specific practices aimed at preventing AECOPD: antibiotics, steroids, antibiotics plus steroids, or no prophylaxis. Subgroups were compared, and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated.ResultsA total of 170 patients were reviewed. The rate of AECOPD was 21.2% for the full cohort. Patients who received prophylaxis had a significantly lower rate of AECOPD compared with those who did not (16.7% vs. 46.2%; p = 0.001). The rate was lowest in patients who received antibiotics alone (9.2%). There was no significant difference in the rate of AECOPD between patients who received steroids alone or antibiotics plus steroids, compared with the other subgroups. The OR for AECOPD was 4.3 (95% CI: 1.8–10.4; p = 0.001) for patients not receiving prophylaxis and 3.9 (95% CI: 1.5–10.1; p = 0.004) for prophylaxis other than antibiotics alone.ConclusionsAdministration of antibiotics after BLVR with EBV was associated with a lower rate of AECOPD. This was not observed with the use of steroids or in combination with antibiotics.
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Loehr, Andrea , Patnaik, Akash , Campbell, David , Shapiro, Jeremy , Bryce, Alan H. , McDermott, Ray , Sautois, Brieuc , Vogelzang, Nicholas J. , Bambury, Richard , Voog, Éric , Zhang, Jingsong , Hussain, Arif , Ryan, Charles J. , Merseburger, Axel S. , Daugaard, Gedske , Heidenreich, Axel , Fizazi, Karim , Higano, Celestia S. , Krieger, Laurence E. , Watkins, Simon P. , Despain, Darrin , Simmons, Andrew D. , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Abida, Wassim , Ryan, Charles J , Daugaard, Gedske , Heidenreich, Axel , Sternberg, Cora N , Watkins, Simon P , Simmons, Andrew D , Golsorkhi, Tony , Bryce, Alan H , Vogelzang, Nicholas J , McDermott, Ray , Patnaik, Akash , Piulats, Josep M.

Mayo Clinic

Clinical Cancer Research | October 1, 2021 | Volume: 27 | Issue: 24 | Pages: 6677-6686

10.1158/1078-0432.ccr-21-2199 | PMID 34598946 Get It

Abstract Purpose: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. While sequencing of tumor tissue is considered the standard for identifying patients with BRCA alterations (BRCA+), plasma profiling may provide a minimally invasive option to select patients for rucaparib treatment. Here, we report clinical efficacy in patients with BRCA+ mCRPC identified through central plasma, central tissue, or local genomic testing and enrolled in TRITON2. Patients and Methods: Patients had progressed after next-generation androgen receptor–directed and taxane-based therapies for mCRPC and had BRCA alterations identified by central sequencing of plasma and/or tissue samples or local genomic testing. Concordance of plasma/tissue BRCA status and objective response rate and prostate-specific antigen (PSA) response rates were summarized. Results: TRITON2 enrolled 115 patients with BRCA+ identified by central plasma (n = 34), central tissue (n = 37), or local (n = 44) testing. Plasma/tissue concordance was determined in 38 patients with paired samples and was 47% in 19 patients with a somatic BRCA alteration. No statistically significant differences were observed between objective and PSA response rates to rucaparib across the 3 assay groups. Patients unable to provide tissue samples and tested solely by plasma assay responded at rates no different from patients identified as BRCA+ by tissue testing. Conclusions: Plasma, tissue, and local testing of mCRPC patients can be used to identify men with BRCA+ mCRPC who can benefit from treatment with the PARP inhibitor rucaparib.